(Q46837666)

25 December 2017

title

Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer (English)

1 reference

25 December 2017

1 reference

Eero J Kumpulainen

1

1 reference

25 December 2017

Pasi P Hirvikoski

series ordinal

2

1 reference

25 December 2017

Risto T Johansson

series ordinal

3

1 reference

25 December 2017

publication date

1 January 2008

1 reference

25 December 2017

published in

Acta Oncologica

1 reference

25 December 2017

volume

47

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

120-123

1 reference

25 December 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

Data quality and quality control of a population-based cancer registry. Experience in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

Are patients diagnosed with breast cancer before age 50 years ever cured?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

De novo malignancy after paediatric renal replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701518074

10.1080/02841860701518074

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017